Guard Therapeutics Announces Top-Line Results from Phase 2b POINTER Study Guard Therapeutics (publ) announced top-line results from the Phase 2b POINTER study, evaluating RMC-035 as a kidn…
IRENA Chief Highlights Key Themes for COP30 Francesco La Camera, Director-General at the International Renewable Energy Agency (IRENA), ex…
FTSE Mixed as UK Lags Global Rally London stocks opened mixed on Monday, with the FTSE 100 edging up 0.1% to 9,651.66 as the UK market lag…
Cedar Key Community Bands Together to Survive Hurricane Season As the hurricane season nears its end, Cedar Key is still recovering from t…
SAHPRA Approves Groundbreaking HIV Prevention Injection The South African Health Products Regulatory Authority (SAHPRA) has approved a new…
Accident Attorney Leader in Spot TV A specialist in accident attorney services with roots in Florida has topped the most-seen spot report …
SAHPRA Approves Lenacapavir For HIV Prevention SAHPRA's approval for lenacapavir is crucial for the country to begin drug rollout, expecte…
Greyhound Racing Industry Defends Sport Amid Wales Ban Plans The greyhound racing industry is pushing back against plans to ban the sport …
Ascletis to Present Study Results at ObesityWeek 2025 Ascletis Pharma Inc. announces multiple poster presentations of its obesity assets, …
Nanoform Partners with Revio Therapeutics Nanoform Finland Plc announced a partnership with Revio Therapeutics to co-develop and commercia…
Amphista Therapeutics Achieves Breakthrough in Cancer Target Degradation Amphista Therapeutics, a leader in next-generation targeted prote…